Patent number: 9546994
Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m
Type:
Grant
Filed:
August 13, 2013
Date of Patent:
January 17, 2017
Assignees:
Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Geseundheit und Umwelt (GmbH), Deutsche Diabetes-Forschungsgesellschaft e.V.—Trager des Deutschen Diabetes-Zentrums Dusseldorf, Eberhard Karls Universitat Tubingen, Medizinische Fakultat
Inventors:
Wolfgang Rathmann, Christian Herder, Thomas Illig, Jerzy Adamski, Rui Wang-Sattler, Zhongao Yu, H.-Erich Wichmann, Hans-Ulrich Haring, Michael Roden, Annette Peters, Christine Meisinger, Martin Hrabe De Angelis, Thomas Meitinger
